MaaT Pharma Announces €9 Million Capital Increase
MaaT Pharma has announced the launch of a global offering of ordinary shares amounting to approximately €9 million, according to a press release dated November 13, 2025.
Details of the Offering
MaaT Pharma, listed on Euronext Paris, has announced a global offering that includes a private placement to qualified investors and a public offering via the PrimaryBid platform. The offering price is set at €3.48 per share, representing a discount of approximately 10% compared to the weighted average of the closing prices of the last three trading sessions. The private placement and the PrimaryBid offer will close on November 14, 2025. Existing shareholders, such as PSIM fund and Biocodex, have committed to subscribe for a total of €3 million. The funds raised will be used primarily to finance the commercialization of Xervyteg in Europe, subject to EMA approval.
Use of Proceeds
The funds raised through the global offering will enable MaaT Pharma to continue the development of its microbiota-focused therapies, including the potential commercialization of Xervyteg. If EMA approval is granted, the company hopes that this commercialization will occur in the second half of 2026. MaaT Pharma also plans to use these resources for its working capital needs and general expenses. With additional funding from the European Investment Bank and commercial partners, the company hopes to secure its cash flow until early 2027.
Market Impact and Future Plans
Pending the closure of the global offering and the announcement of the results, the trading of MaaT Pharma's shares has been suspended on Euronext Paris as of November 13, 2025. The results of this operation will be announced on November 14, 2025. The company continues to explore additional financing opportunities to extend its cash horizon and support its development projects, particularly in the United States. The management hopes that the fundraising will open new avenues for financing and strategic partnerships.
